Ventripoint Diagnostics Ltd. (VPTDF) Stock Price & Analysis
Ventripoint Diagnostics Ltd. (VPTDF) — price $0.0492 (+4.68%), as of the Nov 20, 2026 trading session; market cap $9.49M.
Educational signal · not a buy or sell recommendation · How to read this
Ventripoint Diagnostics Ltd. · VPTDF
VentriPoint Diagnostics Ltd. develops and commercializes the Ventripoint Medical System (VMS), a diagnostic tool for monitoring heart disease globally. The VMS and VMS+ software generate three-dimensional heart models, providing critical volumetric and functional measurements for various cardiac conditions.
Price as of Nov 20, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $0.0492 |
| Change on the day | +4.68% |
| Market capitalisation | $9.49M |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Ventripoint Diagnostics (VPTDF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
2 lenses, 2 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 22, 2026, except a card that shows its own read date.
What is Ventripoint Diagnostics (VPTDF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ventripoint Diagnostics Ltd. (VPTDF) is the company analyzed here. In Q2 FY2026 it reported revenue of C$19,583 and net income of -C$683,000. The market values it at $9.49M.
What do the latest results show for Ventripoint Diagnostics (VPTDF)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of C$19,583.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | C$19,583 | -C$683,000 | -C$0.0037 (diluted) |
| Q1 FY2026 | C$19,583 | -C$683,000 | -C$0.0037 (diluted) |
| Q4 FY2025 | C$4,300 | -C$199,588 | -C$0.0010 (diluted) |
| Q3 FY2025 | C$104,304 | -C$752,084 | -C$0.0045 (diluted) |
What are the financial strengths and risks for Ventripoint Diagnostics (VPTDF)?
Short answer · as of
The distress and quality screens read Piotroski F 5. Trailing ratios: ROE 56.4% · current ratio 0.12 · earnings yield -19.1% · free-cash-flow yield -15.3%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VPTDF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VPTDF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About VPTDF
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
Is VPTDF a good stock to buy?
Stock Expert AI does not rate VPTDF buy, sell or hold. Ventripoint Diagnostics Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VPTDF stock price today?
The last price recorded for Ventripoint Diagnostics Ltd. (VPTDF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for VPTDF?
Evaluate VPTDF on fundamentals, analyst consensus, and risk factors. The company does not currently pay a dividend, aligning with a growth-oriented strategy focused on reinvesting earnings into product development and commercialization. Not financial advice.
How frequently does VPTDF data refresh on this page?
VPTDF's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VPTDF's recent stock price performance?
Ventripoint Diagnostics Ltd. (VPTDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VPTDF overvalued or undervalued right now?
Ventripoint Diagnostics Ltd. (VPTDF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VPTDF before investing?
Before investing in Ventripoint Diagnostics Ltd. (VPTDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VPTDF to a portfolio?
No dossier-level strength is on record for Ventripoint Diagnostics Ltd. (VPTDF) yet — start from the MoonshotScore factor breakdown and the Financials tab on this page. Weigh rewards against risks and diversify. Not financial advice.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 10 figures on this page — 8 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com